Skyler B. Johnson
Rating: 5.0 of 5
( out of 137 reviews )

Skyler B. Johnson, MD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-581-2396
Get Directions

Farmington Health Center

165 N. University Ave.
Farmington , UT 84025
801-213-3200
Get Directions

  • Skyler Johnson

    Skyler Johnson, MD is an Assistant Professor in the Department of Radiation Oncology at the University of Utah Huntsman Cancer Institute. As a physician and researcher, he has sought to improve the lives of both individuals and the community through exemplary care and expertise in the area of health services research. His clinical specialties include prostate cancer and other genitourinary malignancies as well as gastrointestinal malignancies, lung cancer, and lymphoma. His research interests include comparative effectiveness, patient communication, patient education, clinical outcomes, quality of life research, cost-effectiveness, decision analyses, and clinical trial design.

    Dr. Johnson's research interests and passion for cancer care began during medical school at Michigan State University. He then completed a year-long research fellowship at the University of Michigan in the Department of Radiation Oncology. He completed his residency in radiation oncology at Yale, where he served as Chief Resident. While at Yale, he received additional training as a Health Sciences Research Fellow as part of the Yale National Clinical Scholars Program (NCSP) and a member of the Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) group.

    His prior comparative effectiveness research on the use of non-traditional cancer treatments garnered national and international media attention from the lay press and resulted in over 450 news stories. He and members of his research team conducted television, radio, and print interviews with NBC, CNN, NPR, BBC, TIME Magazine, Reader's Digest, among others, and it was also prominently featured in the New York Times. More importantly, the research addressed an unmet need in the oncology medical literature and has been used in health policy documents including the WHO's report on cancer. This research has led to ongoing studies in collaboration with national cancer experts quantifying misinformation and potential for harm contained within cancer articles on social media, accuracy of cancer information using AI chatbots, as well as a multi-institutional study identifying sources of exposure, motivations, and perceptions of complementary and alternative medicine use in cancer. Dr. Johnson continually seeks to improve patient care and patient-physician communication by serving as Chair of the Huntsman Cancer Institute's Genitourinary Cancer Centers Communications and Community Outreach Committee as well as being a member of the NRG Oncology New Investigator Committee and American Society for Radiation Oncology’s (ASTRO) Communications Committee. He is an internationally recognized expert on cancer misinformation, its impacts, and potential solutions, frequently delivering invited lectures at prestigious institutions across the country and participating in multi-institutional forums on health mis- and disinformation.

    Specialties

    Board Certification

    American Board of Radiology (Radiation Oncology)

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 137 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    He has been super with my treatment.

    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    I appreciate his expertise and compassion in dealing with me.

    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    Dr. Johnson and his resident Dr. Jackson Howell were very clear and informative about my treatment options, risks and side effects.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Always professional and to the point

    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    Professional and compassionate doctor, providing extended period of time to answer all my questions. Very impressive.

    HUNTSMAN CANCER CENTER
    Rating: 4 out of 5

    What I said seemed to matter. He made suggestions and had done the homework on my case. I felt attended to.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I would definitely recommend Dr. Johnson for your health care. He has been very professional yet caring!

    FARMINGTON HEALTH CENTER
    Rating: 5 out of 5

    He spent all the time required to answer my questions and alleviate my concern.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    This is a stunning doctor who inspired huge confidence with me at a time when I was hit with hard and sometimes confusing choices.

  • Skyler Johnson, MD is an Assistant Professor in the Department of Radiation Oncology at the University of Utah Huntsman Cancer Institute. As a physician and researcher, he has sought to improve the lives of both individuals and the community through exemplary care and expertise in the area of health services research. His clinical specialties include prostate cancer and other genitourinary malignancies as well as gastrointestinal malignancies, lung cancer, and lymphoma. His research interests include comparative effectiveness, patient communication, patient education, clinical outcomes, quality of life research, cost-effectiveness, decision analyses, and clinical trial design.

    Dr. Johnson's research interests and passion for cancer care began during medical school at Michigan State University. He then completed a year-long research fellowship at the University of Michigan in the Department of Radiation Oncology. He completed his residency in radiation oncology at Yale, where he served as Chief Resident. While at Yale, he received additional training as a Health Sciences Research Fellow as part of the Yale National Clinical Scholars Program (NCSP) and a member of the Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) group.

    His prior comparative effectiveness research on the use of non-traditional cancer treatments garnered national and international media attention from the lay press and resulted in over 450 news stories. He and members of his research team conducted television, radio, and print interviews with NBC, CNN, NPR, BBC, TIME Magazine, Reader's Digest, among others, and it was also prominently featured in the New York Times. More importantly, the research addressed an unmet need in the oncology medical literature and has been used in health policy documents including the WHO's report on cancer. This research has led to ongoing studies in collaboration with national cancer experts quantifying misinformation and potential for harm contained within cancer articles on social media, accuracy of cancer information using AI chatbots, as well as a multi-institutional study identifying sources of exposure, motivations, and perceptions of complementary and alternative medicine use in cancer. Dr. Johnson continually seeks to improve patient care and patient-physician communication by serving as Chair of the Huntsman Cancer Institute's Genitourinary Cancer Centers Communications and Community Outreach Committee as well as being a member of the NRG Oncology New Investigator Committee and American Society for Radiation Oncology’s (ASTRO) Communications Committee. He is an internationally recognized expert on cancer misinformation, its impacts, and potential solutions, frequently delivering invited lectures at prestigious institutions across the country and participating in multi-institutional forums on health mis- and disinformation.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Assistant Professor
    Board Certification
    American Board of Radiology (Radiation Oncology)

    Education history

    Undergraduate Major: Zoology; Minor: Chemistry - Weber State University, Ogden, UT B.S.
    Professional Medical Medicine - Michigan State University College of Human Medicine, East Lansing, MI M.D.
    Internship Internal Medicine - Beaumont Health, Oakwood Hospital, Dearborn, MI Intern
    Residency Radiation Oncology - Yale School of Medicine, New Haven, CT Resident
    Research Fellow National Clinician Scholars Program - Yale School of Medicine, New Haven, CT Research Fellow
    Chief Resident Radiation Oncology - Yale School of Medicine, New Haven, CT Chief Resident
    Certification Clinical Educator, Teaching and Learning Center - Yale School of Medicine, New Haven, CT Certification

    Selected Publications

    Journal Article

    1. Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA (2015). Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol, 38(5), 465-71. (Read full publication)
    2. Jackson WC, Johnson SB, Feng FY, Hamstra DA (2015 Aug). Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol, 38(4), 367-72. (Read full publication)
    3. Loganadane G, Kann BH, Park HS, Johnson SB, Mehra S, Judson BL, Bhatia A, Belkacemi Y, Yarbrough WG, Burtness B, Husain ZA (2019). Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Res, 39(9), 4885-4890. (Read full publication)
    4. Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY (2013). Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 119(18), 3287-94. (Read full publication)
    5. Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK (2017). Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. Eur Urol, 72(5), 738-744. (Read full publication)
    6. Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY (2016). Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol, 69(1), 50-7. (Read full publication)
    7. Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D (2013). The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 86(3), 554-61. (Read full publication)
    8. Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY (2013). Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 85(5), 1246-53. (Read full publication)
    9. Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY (2013 Oct 1). Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys, 87(2), 275-81. (Read full publication)
    10. Johnson SB, Park HS, Gross CP, Yu JB (2018). Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst, 110(1). (Read full publication)
    11. Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB (2017). Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer.LID - 10.1093/jnci/djw281 [doi]. J Natl Cancer Inst, 109(6). (Read full publication)
    12. Joseph Anthony Miccio, MD; Andrew Barsky, MD; Sarah Gao, MD; Vivek Verma, MD; Sonal S. Noticewala, MD, MAS; Vikram Jairam, MD; Skyler B. Johnson, MD; James B. Yu, MD, MHS; James E. Hansen, MD; Sanjay Aneja, MD; Yi An, MD; Roy H. Decker, MD, PhD; S. Bulent Omay, MD; Jing Li, MD, PhD; Goldie A. Kurtz, MD; Michelle Alonso-Basanta, MD, PhD; John Y.K. Lee, MD; Veronica Chiang, MD; Henry S. Park, MD, MPH (2020). Multi-Institutional Retrospective Review of Stereotactic Radiosurgery for Brain Metastasis in Patients with Small Cell Lung Cancer Without Prior Brain-Directed Radiotherapy. J Neurooncol.
    13. Hamstra DA, Johnson SB, Daignault S, Zikmund-Fisher BJ, Taylor JM, Larkin K, Wood A, Fagerlin A (2015 Jan). The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making, 35(1), 27-36. (Read full publication)
    14. Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL (2020). A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas, 49(7), 904-911. (Read full publication)
    15. Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA (2014). Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol, 110(2), 291-7. (Read full publication)
    16. Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB (2016). Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol, 121(2), 294-298. (Read full publication)
    17. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2021). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675. (Read full publication)
    18. Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA (2016). MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia, 18(4), 213-22. (Read full publication)
    19. Johnson SB, Yu JB (2018). Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Curr Oncol Rep, 20(9), 66. (Read full publication)
    20. Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann B (2021). Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate cancer and prostatic diseases, 24(2), 414-422. (Read full publication)
    21. Johnson SB, Decker R (2018). Prophylactic Cranial Irradiation Versus Surveillance: Physician Bias and Patient-centered Decision-making. Clinical lung cancer, 19(6), 464-466. (Read full publication)
    22. Johnson SB, Zhou J, Jolly S, Guo B, Young L, Prisciandaro J (2014). The dosimetric impact of single, dual, and triple tandem applicators in the treatment of intact uterine cancer. Brachytherapy, 13(3), 268-74. (Read full publication)
    23. Kann BH, Park HS, Johnson SB, Chiang VL, Yu J (2017). Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. Journal of the National Comprehensive Cancer Network, 15(12), 1494-1502. (Read full publication)
    24. Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng F (2013). A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiation oncology (London, England), 8, 170. (Read full publication)
    25. Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra D (2014). Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiation oncology (London, England), 9, 245. (Read full publication)
    26. Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng F (2014). Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Practical radiation oncology, 4(2), 99-107. (Read full publication)
    27. Johnson S, Jackson W, Speers C, Feng F, Hamstra (2014). A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Practical radiation oncology, 4(6), 422-9. (Read full publication)
    28. Johnson SB, Hung J, Kapadia N, Oh KS, Kim M, Hamstra D (2019). Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. Practical radiation oncology, 9(1), e22-e28. (Read full publication)
    29. Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel A (2019). Overall survival is improved when DCIS accompanies invasive breast cancer. Scientific reports, 9(1), 9934. (Read full publication)
    30. Johnson SB, Park HS, Gross CP, Yu J (2018). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA oncology, 4(10), 1375-1381. (Read full publication)
    31. Johnson SB, Gross CP, Yu J (2019). Methodology Flaws and Implications of a Complementary Medicine Study-In Reply. JAMA oncology, 5(3), 433. (Read full publication)
    32. Benjamin H. Kann, MD, Skyler B. Johnson, MD, Hugo J.W.L. Aerts, PhD, Raymond H. Mak, MD, Paul L. Nguyen, M (2020). Changes in Length and Complexity of Clinical Practice Guidelines in Oncology, 1996-2019. JAMA network open,
    33. Parsons MW, Hutten RJ, Tward A, Khouri A, Peterson J, Morrell G, Lloyd S, Cannon DM, Johnson S (2022). The Effect of Maximum Tumor Diameter by MRI on Disease Control in Intermediate and High-risk Prostate Cancer Patients Treated With Brachytherapy Boost. Clinical genitourinary cancer, 20(1), e68-e74. (Read full publication)
    34. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson S (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical genitourinary cancer, 19(6), e360-e366. (Read full publication)
    35. Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin (2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, 114(7), 1036-1039. (Read full publication)
    36. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33. (Read full publication)
    37. Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Bulent Omay S, Li J, Kurtz GA, Alonso-Basanta M, Lee JYK, Chiang VL, Park H (2020). Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. Journal of radiosurgery and SBRT, 7(1), 19-27. (Read full publication)
    38. Hutten RJ, Nelson G, Sarkar V, Johnson SB, Tao R, Hitchcock Y, Chan J, Schroeder J, Kokeny (2022). Feasibility and clinical utility of a workflow interfacing radiation oncology lung stereotactic body radiotherapy treatment planning and diagnostic radiology. Practical radiation oncology, 12(6), e512-e516. (Read full publication)
    39. Seymour ZA, Daignault-Newton S, McLaughlin PW, Sandler H, Jackson W, Johnson SB, Miller D, Wei J, Sanda M, Hamstra D (2022). Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clinical and translational radiation oncology, 36, 56-62. (Read full publication)
    40. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, O'Neil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, 20(6), e453-e459. (Read full publication)
    41. Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson (2022). Timing and Motivations for Alternative Cancer Therapy With Insights From a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR cancer, 8(2), e34183. (Read full publication)
    42. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer, 54(2), 492-500. (Read full publication)
    43. Seymour ZA,Daignault-Newton S,McLaughlin PW,Sandler H,Jackson W,Johnson SB,Miller D,Wei J,Sanda M,Hamstra D (2022). Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clinical and translational radiation oncology, 36, 56-62. (Read full publication)
    44. Peterson J,Wilson T,Gruhl J,Davis S,Olsen J,Parsons M,Kann B,Fagerlin A,Watt M,Johnson (2022). Timing and Motivations for Alternative Cancer Therapy with Insights from a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR cancer, 8(2), (Read full publication)
    45. Hutten R,Khouri A,Parsons M,Tward A,Wilson T,Peterson J,Morrell G,Dechet C,O'Neil B,Schmidt B,Kokeny K,Lloyd S,Cannon D,Tward J,Sanchez A,Johnson (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clinical genitourinary cancer, (Read full publication)
    46. Parsons M,Lloyd S,Johnson S,Scaife C,Soares H,Kim R,Kim R,Garrido-Laguna I,Tao (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. Journal of gastrointestinal cancer, (Read full publication)
    47. Miccio JA,Barsky A,Gao S,Verma V,Noticewala SS,Jairam V,Johnson SB,Yu JB,Hansen JE,Aneja S,An Y,Decker RH,Omay SB,Li J,Kurtz GA,Alonso-Basanta M,Lee JYK,Chiang VL,Park H (2020). Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small-cell lung cancer without prior brain-directed radiotherapy. Journal of radiosurgery and SBRT, 7(1), 19-27. (Read full publication)
    48. Johnson S,Park H,Gross C,Yu (2019). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. Obstetrical & gynecological survey, 74(4), 217-219. (Read full publication)
    49. Weil CR,Parsons MJ,Hutten RJ,Lew FH,Johnson SB,Gaffney DK,Tao (2022). Patterns of care and outcomes of early stage I'II Hodgkin lymphoma treated with or without radiation therapy. Leukemia & lymphoma, (Read full publication)
    50. Bylund CL, Mullis MD, Alpert J, Markham MJ, Onega T, Fisher CL, Johnson S (2023). Clinician Communication With Patients About Cancer Misinformation: A Qualitative Study. JCO oncology practice, 19(3), OP2200526. (Read full publication)
    51. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & lymphoma, 64(2), 1-8. (Read full publication)
    52. Peterson JS, Plana D, Bitterman DS, Johnson SB, Aerts HJWL, Kann B (2022). Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials. Cancer medicine, (Read full publication)
    53. Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund C (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI cancer spectrum, 7(2), (Read full publication)
    54. Johnson SB, Bylund C (2023). Identifying Cancer Treatment Misinformation and Strategies to Mitigate Its Effects With Improved Radiation Oncologist-Patient Communication. Practical radiation oncology, (Read full publication)
    55. Peterson J, Wilson TF, Watt MH, Gruhl J, Davis S, Olsen J, Parsons MW, Kann BH, Swire-Thompson B, Fagerlin A, Warner EL, King AJ, Chino F, Johnson S (2023). International medical tourism of US cancer patients for alternative cancer treatments: Financial, demographic, and clinical profiles of online crowdfunding campaigns. Cancer Med, 12(7), 8871-8879. (Read full publication)
    56. Hutten RJ,Weil CR,King AJ,Barney B,Bylund CL,Fagerlin A,Gaffney DK,Gill D,Scherer L,Suneja G,Tward JD,Warner EL,Werner TL,Whipple G,Evans J,Johnson S (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO oncology practice, 19(11), 1000-1008. (Read full publication)
    57. Johnson SB,King AJ,Warner EL,Aneja S,Kann BH,Bylund C (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI cancer spectrum, 7(2), (Read full publication)
    58. Fridman I,Johnson S,Elston Lafata (2023). Health Information and Misinformation: A Framework to Guide Research and Practice. JMIR medical education, 9, (Read full publication)
    59. Fridman I, Johnson S, Elston Lafata (2023). Health Information and Misinformation: A Framework to Guide Research and Practice. JMIR medical education, 9, e38687. (Read full publication)
    60. Hutten RJ, Odei B, Johnson SB, Tward J (2024). Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO precision oncology, 8, e2300364. (Read full publication)
    61. Bylund CL, Taylor G, Vasquez TS, Alpert J, Johnson SB, Le T, Paige SR, Close J, Markham M (2024). Talking with clinicians about online cancer information: a survey of cancer patients and surrogate information seekers. Supportive care in cancer, 32(6), 362. (Read full publication)
    62. Mullis MD,Fisher CL,Johnson SB,Liu T,Amin TB,Rogers S,DeGruccio K,Bylund C (2024). Clinician-patient communication about cancer treatment misinformation: The Misinformation Response Model. PEC innovation, 5, (Read full publication)
    63. Roach E,Hutten R,Johnson S,Suneja G,Tward J,Petereit D,Gaffney (2024). The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy. Brachytherapy, 23(3), 360-367. (Read full publication)
    64. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR study. International journal of radiation oncology, biology, physics, (Read full publication)
    65. Swire-Thompson B, Kilgallen K, Dobbs M, Bodenger J, Wihbey J, Johnson (2024). Discrediting health disinformation sources: Advantages of highlighting low expertise. Journal of experimental psychology. General, 153(9), 2299-2313. (Read full publication)
    66. Fridman I, Smith C, Barrett A, Johnson S, Bhowmick A, Hayes S, Elston Lafata (2025). Navigating Disagreements on Health Information: How Patients With Cancer Perceive Health Care Providers' Approaches to Discussing Patient-Identified Information. JCO oncology practice, OP2400071. (Read full publication)
    67. Parker ND, Johnson SB, King AJ, Amin TB, Swire-Thompson B, Zhang Z, Bylund C (2025). Assessing Cancer Patients' Exposure to Treatment Misinformation. Journal of cancer education, (Read full publication)
    68. Huisman KM, Whitaker MK, Johnson SB, Walker G (2025). Paging Dr. Google: Characterizing Direct-to-Consumer Digital Advertisements From Oncology Treatment Centers. Cureus, 17(3), e80994. (Read full publication)
    69. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13. (Read full publication)
    70. Turner CA, King AJ, Tovar I, Millar MM, Codden RR, Guo JW, Johnson S, Kirchhoff AC, Raber M, Sheng X, Kepka D, Warner E (2025). Evaluating the Feasibility of Web-Monitoring Methodology for Measuring Exposure to Online Cancer Misinformation. JMIR cancer, 11, e65887. (Read full publication)
    71. Fridman I, Johnson SB, Derry-Vick H (2025). When Limited Clinical Time With Patients Meets Unlimited Online Information. JMIR cancer, 11, e79031. (Read full publication)
    72. Howell JN, Wilkes J, Maughan NM, Patel RB, Barney B, Taunk NK, Escorcia FE, Johnson SB, Boothe (2025). Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade. International journal of radiation oncology, biology, physics, (Read full publication)

    Review

    1. Ford KL,Orsso CE,Kiss N,Johnson SB,Purcell SA,Gagnon A,Laviano A,Prado C (2022). Dietary choices after a cancer diagnosis: A narrative review. Nutrition (Burbank, Los Angeles County, Calif.), 103-104, 111838. (Read full publication)
    2. Swire-Thompson B,Johnson (2024). Cancer: A model topic for misinformation researchers. Current opinion in psychology, 56, (Read full publication)

    Book Chapter

    1. Johnson SB, Damast S, Young (2016). Cervical Cancer.
    2. Johnson SB, Decker R (2017). Radiation Therapy. 157.

    Case Report

    1. Johnson SB, Prisciandaro JI, Zhou J, Hadley SW, Reynolds RK, Jolly S (2014). Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report. J Appl Clin Med Phys, 15(1), 4520. (Read full publication)

    Editorial

    1. Johnson SB, Decker R (2018). Prophylactic Cranial Irradiation Versus Surveillance:: Physician Bias in Prophylactic Cranial Irradiation (PCI) Decision Making-Opportunity for a Patient Decision Aid. Clinical lung cancer,
    2. Peterson JS, Swire-Thompson B, Johnson S (2020). What is the alternative? Responding strategically to cancer misinformation. Future oncology (London, England), 16(25), 1883-1888. (Read full publication)

    Letter

    1. Hutten RJ,Weil CR,Tward JD,Lloyd S,Johnson S (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European urology open science, 23, 30-33. (Read full publication)

    Research Lab

  • News & Podcasts

    Huntsman Cancer Institute News